GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » EV-to-Revenue

Argenica Therapeutics (ASX:AGN) EV-to-Revenue : (As of Jun. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Argenica Therapeutics's enterprise value is A$94.24 Mil. Argenica Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Therefore, Argenica Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Argenica Therapeutics's EV-to-Revenue or its related term are showing as below:

ASX:AGN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-22), Argenica Therapeutics's stock price is A$0.83. Argenica Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Argenica Therapeutics's PS Ratio for today is .


Argenica Therapeutics EV-to-Revenue Historical Data

The historical data trend for Argenica Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics EV-to-Revenue Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
EV-to-Revenue
- - -

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Argenica Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Argenica Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argenica Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's EV-to-Revenue falls into.



Argenica Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Argenica Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=94.244/0
=

Argenica Therapeutics's current Enterprise Value is A$94.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Argenica Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argenica Therapeutics  (ASX:AGN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Argenica Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.83/0
=

Argenica Therapeutics's share price for today is A$0.83.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argenica Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines